GRCE catalyst calendar

Grace Therapeutics, Inc.

Upcoming catalysts
1
Cash runway
12.8 months
Cash & investments
$14M
Phase 3 programs
3

Grace Therapeutics, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.

The next scheduled catalyst is Next quarterly earnings (projected) on November 12, 2026, a projected date rather than a confirmed one. There is 1 upcoming event on record.

Cash runway is approximately 12.8 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.

Across 5 concluded trials, 100% reached completion rather than being terminated or withdrawn.

Upcoming catalysts

DateEventTypePhase
November 12, 2026 est. Next quarterly earnings (projected) Earnings —

Track GRCE alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open GRCE in the tracker

Recent history

DateEventTypePhase
August 13, 2026 Quarterly results filed (8-K) Earnings —
August 6, 2026 8-K filed: Material agreement, Other event Corporate —
July 28, 2026 8-K filed: Other event Filing —
June 18, 2026 Quarterly results filed (8-K) Earnings —
June 18, 2026 8-K filed: Other event Filing —
June 5, 2026 8-K filed: Leadership change Corporate —
April 27, 2026 8-K filed: Other event Filing —
April 23, 2026 8-K filed: Other event Filing —
February 12, 2026 Quarterly results filed (8-K) Earnings —
January 12, 2026 8-K filed: Leadership change Corporate —
November 13, 2025 Quarterly results filed (8-K) Earnings —
October 23, 2025 8-K filed: Other event Filing —
September 18, 2025 8-K filed: Other event Filing —
August 27, 2025 8-K filed: Other event Filing —
August 12, 2025 Quarterly results filed (8-K) Earnings —
June 25, 2025 8-K filed: Other event Filing —
June 23, 2025 Quarterly results filed (8-K) Earnings —
December 15, 2024 Safety and Tolerability of GTX-104 Compared with Oral Nimodipine in Patients with ASAH Trial Milestone Phase 3
February 17, 2022 Relative Bioavailability of Intravenous GTX-104 Compared to Oral Nimodipine Capsules in Healthy Subjects Trial Milestone Phase 1
September 24, 2019 A Phase 3 STudy of CaPRe in LOwering Very hiGh TriglYcerides (TRILOGY 2) Trial Milestone Phase 3
July 21, 2019 A Phase 3 STudy of CaPRe In LOwering Very hiGh TriglYcerides (TRILOGY 1) Trial Milestone Phase 3

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.